Multiple Alzheimer's disease-related targets

Multiple Alzheimer's disease-related targets refers to a collective group of molecular entities and pathways that contribute to the complex, multifaceted pathology of Alzheimer's disease (AD). This group includes enzymes such as acetylcholinesterase (AChE), butyrylcholinesterase (BChE), and beta-secretase 1 (BACE1), as well as structural proteins like amyloid-beta (Aβ) and tau, and various receptors including NMDA and nicotinic acetylcholine receptors. The therapeutic strategy involving these targets often focuses on 'multi-target directed ligands' (MTDLs) or combination therapies designed to address the diverse hallmarks of AD, such as cholinergic deficiency, amyloid plaque accumulation, neurofibrillary tangles, and chronic neuroinflammation. By simultaneously modulating several of these targets, researchers aim to achieve superior disease-modifying effects compared to traditional single-target approaches. Current treatments like cholinesterase inhibitors and NMDA antagonists provide symptomatic relief, while newer monoclonal antibodies target Aβ clearance to slow cognitive decline.

Other names

AD multi-targetsMulti-target directed ligands (MTDL) targetsAlzheimer's disease polypharmacology targetsAD-related protein targets

Inhibition of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), NMDA receptor antagonism, inhibition of beta-secretase 1 (BACE1), clearance of amyloid-beta (Aβ) plaques, inhibition of tau protein aggregation, and modulation of neuroinflammatory pathways (e.g., TNF-alpha inhibition).